(FIGS) Figs - Overview
Sector: Consumer Cyclical | Industry: Apparel Manufacturing | Exchange: NYSE (USA) | Market Cap: 1.918m USD | Total Return: 182.4% in 12m
Avg Turnover: 54.7M
EPS Trend: -0.6%
Qual. Beats: 0
Rev. Trend: 85.2%
Qual. Beats: 0
Warnings
Share dilution 20.7% YoY
Tailwinds
Leader, Tailwind
FIGS, Inc. is a direct-to-consumer (DTC) healthcare apparel company that designs and markets premium scrubwear, non-scrubwear, and lifestyle accessories. Headquartered in Santa Monica, California, the company utilizes a proprietary digital platform and mobile app to sell directly to healthcare professionals, bypassing traditional third-party medical distributors. Its product catalog extends beyond core medical uniforms to include performance outerwear, compression socks, and specialized bags tailored for clinical environments.
The company operates within the specialized medical apparel sector, which has historically been dominated by legacy brands selling through wholesale channels. By employing a DTC business model, FIGS maintains control over its brand identity and captures higher margins through vertical integration. This strategy leverages the recurring nature of medical apparel purchases, as scrubs are functional necessities that require frequent replacement due to wear and hygiene requirements.
For a detailed breakdown of the companys valuation metrics and historical performance, consider reviewing the comprehensive data available on ValueRay. Analysts should monitor the companys expansion into international markets and its physical retail footprint as primary drivers for future revenue diversification.
- Active healthcare professional customer base growth drives direct-to-consumer revenue
- Expansion into international markets scales global brand awareness and sales
- Product diversification into non-scrubwear lifestyle categories increases average order value
- Marketing spend efficiency and customer acquisition costs impact operating margins
- Global supply chain disruptions and freight costs influence gross profit stability
| Net Income: 40.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -4.67 > 1.0 |
| NWC/Revenue: 52.84% < 20% (prev 53.24%; Δ -0.39% < -1%) |
| CFO/TA 0.09 > 3% & CFO 48.7m > Net Income 40.6m |
| Net Debt (-216.4m) to EBITDA (60.3m): -3.59 < 3 |
| Current Ratio: 5.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (196.1m) vs 12m ago 20.70% < -2% |
| Gross Margin: 66.10% > 18% (prev 0.67%; Δ 6.54k% > 0.5%) |
| Asset Turnover: 122.7% > 50% (prev 107.4%; Δ 15.26% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 432.2m - Total Current Liabilities 80.2m) / Total Assets 563.4m |
| B: 0.19 (Retained Earnings 105.0m / Total Assets 563.4m) |
| C: 0.09 (EBIT TTM 49.8m / Avg Total Assets 542.9m) |
| D: 0.79 (Book Value of Equity 104.9m / Total Liabilities 132.8m) |
| Altman-Z'' = 6.15 = AAA |
| DSRI: 0.67 (Receivables 5.24m/6.55m, Revenue 666.1m/561.2m) |
| GMI: 1.02 (GM 66.10% / 67.35%) |
| AQI: 0.96 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 666.1m / 561.2m) |
| TATA: -0.01 (NI 40.6m - CFO 48.7m) / TA 563.4m) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of May 25, 2026, the stock is trading at USD 12.44 with a total of 2,161,211 shares traded.
Over the past week, the price has changed by +6.54%,
over one month by -24.05%,
over three months by +14.42% and
over the past year by +182.43%.
Figs has received a consensus analysts rating of 2.90. Therefore, it is recommended to hold FIGS.
- StrongBuy: 0
- Buy: 1
- Hold: 7
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 17.6 | 41.7% |
P/E Forward = 45.045
P/S = 2.879
P/B = 4.4531
Revenue TTM = 666.1m USD
EBIT TTM = 49.8m USD
EBITDA TTM = 60.3m USD
Long Term Debt = 52.3m USD (estimated: total debt 60.6m - short term 8.27m)
Short Term Debt = 8.27m USD (from shortTermDebt, last quarter)
Debt = 60.6m USD (from shortLongTermDebtTotal, last quarter) (leases 60.6m already included)
Net Debt = -216.4m USD (calculated: Debt 60.6m - CCE 277.0m)
Enterprise Value = 1.70b USD (1.92b + Debt 60.6m - CCE 277.0m)
Interest Coverage Ratio = unknown (Ebit TTM 49.8m / Interest Expense TTM 0.0)
EV/FCF = 43.13x (Enterprise Value 1.70b / FCF TTM 39.4m)
FCF Yield = 2.32% (FCF TTM 39.4m / Enterprise Value 1.70b)
FCF Margin = 5.92% (FCF TTM 39.4m / Revenue TTM 666.1m)
Net Margin = 6.10% (Net Income TTM 40.6m / Revenue TTM 666.1m)
Gross Margin = 66.10% ((Revenue TTM 666.1m - Cost of Revenue TTM 225.8m) / Revenue TTM)
Gross Margin QoQ = 65.59% (prev 62.94%)
Tobins Q-Ratio = 3.02 (Enterprise Value 1.70b / Total Assets 563.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 60.6m)
Taxrate = 2.44% (157k / 6.45m)
NOPAT = 48.6m (EBIT 49.8m * (1 - 2.44%))
Current Ratio = 5.39 (Total Current Assets 432.2m / Total Current Liabilities 80.2m)
Debt / Equity = 0.14 (Debt 60.6m / totalStockholderEquity, last quarter 430.6m)
Debt / EBITDA = -3.59 (Net Debt -216.4m / EBITDA 60.3m)
Debt / FCF = -5.49 (Net Debt -216.4m / FCF TTM 39.4m)
Total Stockholder Equity = 419.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.49% (Net Income 40.6m / Total Assets 563.4m)
RoE = 9.69% (Net Income TTM 40.6m / Total Stockholder Equity 419.5m)
RoCE = 10.56% (EBIT 49.8m / Capital Employed (Equity 419.5m + L.T.Debt 52.3m))
RoIC = 10.56% (NOPAT 48.6m / Invested Capital 460.5m)
WACC = 8.00% (E(1.92b)/V(1.98b) * Re(8.25%) + D(60.6m)/V(1.98b) * Rd(0.0%) * (1-Tc(0.02)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 15.56 | Cagr: 3.37%
[DCF] Terminal Value 73.10% ; FCFF base≈48.0m ; Y1≈42.1m ; Y5≈34.0m
[DCF] Fair Price = 4.80 (EV 546.4m - Net Debt -216.4m = Equity 762.8m / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -0.65 | EPS CAGR: -0.66% | SUE: 0.42 | # QB: 0
Revenue Correlation: 85.25 | Revenue CAGR: 6.52% | SUE: 0.55 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+1.78% | Revisions=+14% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=-4.81% | Revisions=-14% | Analysts=8
EPS current Year (2026-12-31): EPS=0.27 | Chg30d=+6.38% | Revisions=+50% | GrowthEPS=+40.3% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=0.32 | Chg30d=+8.11% | Revisions=+38% | GrowthEPS=+20.5% | GrowthRev=+7.9%
[Analyst] Revisions Ratio: +50%